|
|
Post by mnholdem on Feb 22, 2020 21:25:08 GMT -5
Yes and 40%...minimum. That's not how I'd make Afrezza a blockbuster though. That would have been only the beginning.
|
|
|
|
Post by longliner on Feb 22, 2020 21:30:35 GMT -5
Yes and 40%...minimum. That's not how I'd make Afrezza a blockbuster though. That would have been only the beginning. Wow....it's great to hear we could have sold it at a loss this whole time! What were they thinking? (Please don't edit my words, I don't care if you delete them, just don't change them). |
|
|
|
Post by mnholdem on Feb 22, 2020 21:41:59 GMT -5
Why in the world would I edit your words?
Anyway, I happen to know what the cost to manufacture Afrezza is. In, fact, I'll bet that several long term stockholders besides me remember how Pfeffer inadvertently disclosed it and later admitted his slip. I had nearly nailed it anyway because one of companies in the group I work for manufactures medical-grade plastics and devices.
Sell Afrezza at a loss? Laughable. With a 40% retail reduction, MannKind COGS would still be generating a healthy margin.
|
|
|
|
Post by longliner on Feb 22, 2020 21:49:57 GMT -5
Why in the world would I edit your words? Anyway, I happen to know what the cost to manufacture Afrezza is. In, fact, I'll bet that several long term stockholders besides me remember how Pfeffer inadvertently disclosed it and later admitted his slip. I had nearly nailed it anyway because one of companies in the group I work for manufactures medical-grade plastics and devices. Sell Afrezza at a loss? Laughable. With a 40% retail reduction, MannKind COGS would still be generating a healthy margin. I don't know why. Do the math.......that would mean we are profitable at the absorbitant price currently charged? I agree with you, if you are willing to take a greater loss short term to build client (patient) base long term. However, you can't have it both ways, you say on one hand there is not sufficient patient retention, but at the same time you would slash the price. Perfect world? Or the one we live in? And please don't reference VDex as there is simply no coroboration from them of any patient base at all. |
|
|
|
Post by mnholdem on Feb 22, 2020 22:02:43 GMT -5
Correct! Afrezza is profitable. Unfortunately, the company needs the generate considerably greater sales volume just to cover Sales, General and Administrative (SG&A) expenses. I have been doing the math for many years.  |
|
|
|
Post by longliner on Feb 22, 2020 22:10:22 GMT -5
Correct! Afrezza is profitable. Unfortunately, the company needs the generate considerably greater sales volume just to cover Sales, General and Administrative (SG&A) expenses. I have been doing the math for many years. Yes, Afrezza is. Obviously I invest in Mannkind as I assume all the other (real) investors here do too. When the cash flow positive moniker pops up I and my fellow longs (you) will be ecstatic. Afrezza does not sell in a vacuum, Mannkind as well does not operate in a vacuum! |
|
|
|
Post by mnholdem on Feb 22, 2020 22:12:57 GMT -5
Also, it's a valid argument that poor patient retention has been affected by the premium price that MannKind has elected. Winning BPM coverage any time soon is problematic. Fortunately Afrezza is so good that many would pay out of pocket when denied coverage...if they could afford it.
They simply can't afford it.
|
|
|
|
Post by longliner on Feb 22, 2020 22:23:54 GMT -5
Also, it's a valid argument that poor patient retention has been affected by the premium price that MannKind has elected. Winning BPM coverage any time soon is problematic. Fortunately Afrezza is so good that many would pay out of pocket when denied coverage...if they could afford it. They simply can't afford it. The screaming now is at a crescendo. Until insurance / PBM's come around, a price drop would be met with folks howling for the CEO's head.  |
|
|
|
Post by mnholdem on Feb 22, 2020 22:44:45 GMT -5
Which brings us back to the origin of this thread. Price-fixing at the expense of people who need insulin in order to live. Sure, few stockholders would rant, but how many people with diabetes would hail the CEO as a hero? So, having redirected this thread back toward the RICO article, let me say that we all know that none of the executives of the Big 3 will ever serve prison time and that it's likely that any fines, no matter how large, would never approach the profits the giant companies have raked in from their dramatic increases of insulin prices. Nite!  |
|
|
|
Post by lifebreath on Feb 22, 2020 23:00:59 GMT -5
Also, it's a valid argument that poor patient retention has been affected by the premium price that MannKind has elected. Winning BPM coverage any time soon is problematic. Fortunately Afrezza is so good that many would pay out of pocket when denied coverage...if they could afford it. They simply can't afford it. The screaming now is at a crescendo. Until insurance / PBM's come around, a price drop would be met with folks howling for the CEO's head. many here are howling for his head due to the lack of retention, which is MC’s greatest failure. His loyal fans make one excuse after the other but the truth is he needs to be held accountable. Greater retention = lower pricing |
|
|
|
Post by prcgorman2 on Feb 22, 2020 23:22:05 GMT -5
Would lowering the cost increase sales? It might. It better since the revenue would be reduced. Would lowering the price materially improve support from the insurance companies? That to me is the key question. If the answer is no, then you’re betting price alone is the most important barrier to retention. That’s a big bet. If you get it wrong, now you’re really in the soup. What do you do? Oh, sorry, I guessed wrong, I need to increase the price. Oy veh.
|
|
|
|
Post by longliner on Feb 22, 2020 23:27:28 GMT -5
The screaming now is at a crescendo. Until insurance / PBM's come around, a price drop would be met with folks howling for the CEO's head. many here are howling for his head due to the lack of retention, which is MC’s greatest failure. His loyal fans make one excuse after the other but the truth is he needs to be held accountable. Greater retention = lower pricing All hail the great and mighty VDEX............share some numbers or fade away. All ten of you. |
|
|
|
Post by lifebreath on Feb 22, 2020 23:47:28 GMT -5
many here are howling for his head due to the lack of retention, which is MC’s greatest failure. His loyal fans make one excuse after the other but the truth is he needs to be held accountable. Greater retention = lower pricing All hail the great and mighty VDEX............share some numbers or fade away. What is Mnkd’s retention rate? |
|
|
|
Post by longliner on Feb 22, 2020 23:48:34 GMT -5
All hail the great and mighty VDEX............share some numbers or fade away. What is Mnkd’s retention rate? What is VDEX's patient base?  Oh my, business reasons...........what will you say?  |
|
|
|
Post by mytakeonit on Feb 23, 2020 0:39:00 GMT -5
You all are going around and around what I have been saying for a long time. Which is? I'm not saying because no one listens. But, for those that do listen ... Mike C has always said that Afrezza is cheap to make. The response was that endos listen to what BP says. Only a few who saw the light were getting on the band wagon. This CC should shed a lot of light. So, I have my sunglasses at my side. But, that's mytakeonit |
|
Oh my, business reasons...........what will you say?
